{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T15:03:27Z","timestamp":1724943807427},"reference-count":66,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T00:00:00Z","timestamp":1296691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Oncology"],"published-print":{"date-parts":[[2011,4]]},"abstract":"<jats:p>Outcome in melanoma patients with advanced disease is poor and systemic treatment seems to benefit only a subset of patients. Predictive markers identifying these patients are currently not available. Early studies showed an association of immune\u2010related side effects such as vitiligo and autoimmune thyroiditis with response to IL\u20102 or IFN\u03b1 treatment. However, conflicting data have been reported as well, mentioning the effect of a higher rate of immune\u2010related toxicities during prolonged administration of the drug in responders. The review discusses the prognostic significance of autoimmunity during various forms of immunotherapy and stresses the importance of correcting for guarantee\u2010time bias. In addition, other immune\u2010related factors which have been associated with melanoma prognosis such as, CRP, white blood cell count, absolute lymphocyte count and human leukocyte antigen will be reviewed as well. A better understanding of the immune system and the host\u2010tumor interactions should ultimately lead to more effective treatment. A major challenge expected to be addressed in future is proving ways to uncouple tumor immunity from autoimmunity.<\/jats:p>","DOI":"10.1016\/j.molonc.2011.01.004","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T09:15:50Z","timestamp":1296810950000},"page":"183-189","source":"Crossref","is-referenced-by-count":18,"title":["Immunologic functions as prognostic indicators in melanoma"],"prefix":"10.1002","volume":"5","author":[{"given":"Marna G.","family":"Bouwhuis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo L.M.","family":"ten Hagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.710"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198806163182401"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.205"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.04.165"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4799"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19831115)52:10<1841::AID-CNCR2820521014>3.0.CO;2-N"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700545"},{"key":"e_1_2_9_10_1","doi-asserted-by":"crossref","unstructured":"Bouwhuis M.G. Suciu S. Testori A. Kruit W.H. Sales F. Patel P. et\u00a0al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies\u2013EORTC 18991. J. Clin. Oncol. 28 2460\u20132466.","DOI":"10.1200\/JCO.2009.24.6264"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp132"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1717"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2435"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328339da1e"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602043"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0187"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.04.030"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.03.009"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67482-X"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0554"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053007"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25211"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115611"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(07)70097-6"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.5.1609"},{"key":"e_1_2_9_26_1","unstructured":"Hersh E.M. O'Day S.J. Powderly J. Khan K.D. Pavlick A.C. Cranmer L.D. et\u00a0al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest. New Drugs."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_9_28_1","first-page":"113","article-title":"Incidence of circulating antinuclear antibodies in cancer patients","volume":"57","author":"Imran A.","year":"2003","journal-title":"Indian J. Med. Sci."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118032985"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2033"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199511000-00008"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.5.921"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","unstructured":"Ku G.Y. Yuan J. Page D.B. Schroeder S.E. Panageas K.S. Carvajal R.D. et\u00a0al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116 1767\u20131775.","DOI":"10.1002\/cncr.24951"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910590413"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960815)78:4<758::AID-CNCR11>3.0.CO;2-U"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02573896"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199511000-00005"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf257"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq013"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.15.3477"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206462"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21854"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199601000-00009"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199809000-00004"},{"key":"e_1_2_9_45_1","first-page":"1","article-title":"HLA-DQ1 is associated with clinical response and survival of patients with melanoma who are treated with interleukin-2","volume":"2","author":"Rubin J.T.","year":"1995","journal-title":"Ther. Immunol."},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22951"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(90)90275-X"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-199406000-00008"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602702"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0274"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.120"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203304lu521oa"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2002.0320s1079.x"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2007.25.18_suppl.8506"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400909"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1994.175"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1697"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090535"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00327-8"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18811.x"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)90006-6"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.1927"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1024"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1376"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161502"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70334-1"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200839152"}],"container-title":["Molecular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.molonc.2011.01.004","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.molonc.2011.01.004","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1574789111000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1574789111000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.molonc.2011.01.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T13:20:38Z","timestamp":1695475238000},"score":1,"resource":{"primary":{"URL":"https:\/\/febs.onlinelibrary.wiley.com\/doi\/10.1016\/j.molonc.2011.01.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,3]]},"references-count":66,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["10.1016\/j.molonc.2011.01.004"],"URL":"https:\/\/doi.org\/10.1016\/j.molonc.2011.01.004","archive":["Portico"],"relation":{},"ISSN":["1574-7891","1878-0261"],"issn-type":[{"value":"1574-7891","type":"print"},{"value":"1878-0261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,3]]}}}